Form 4: Biote Corp. Executive Chairman Marc Beer Granted Stock Options

Executive Chairman of Biote Corp., Marc D. Beer, was granted stock options for 495,600 shares of Class A Common Stock on April 1, 2025, according to a Form 4 filing.

Summary

• Marc D. Beer, Executive Chairman of Biote Corp., was granted an employee stock option to purchase 495,600 shares of Class A Common Stock.
• The options were granted on April 1, 2025, with an exercise price of $3.63 per share.
• 25% of the options will vest on April 1, 2026, and the remaining shares will vest in 36 substantially equal monthly installments thereafter, contingent upon continuous service.
• The options expire on March 31, 2035.
• A Power of Attorney was previously executed on May 26, 2022, authorizing certain individuals to file SEC forms on Beer's behalf.

Sentiment

Score: 6

Explanation: The document is neutral in sentiment. It simply reports a stock option grant, which is a routine corporate action. The impact is slightly positive as it incentivizes management.

Positives

• The granting of stock options aligns the Executive Chairman's interests with those of the shareholders.
• The vesting schedule incentivizes continued service and commitment to the company.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the stock options.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with shareholder value.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• The size and vesting schedule of the grant are typical for executive-level positions, aligning with industry practices for incentivizing long-term performance.
• Comparing the exercise price and vesting schedule to similar companies like Amgen, Gilead Sciences, or Regeneron would provide a more detailed benchmark.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the Executive Chairman to drive company performance.
• Employees may see the grant as a sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, Form 4, Biote Corp, BTMD, Marc D. Beer, executive compensation, insider trading, beneficial ownership, vesting